Annual report

Period2024-07-01 → 2025-06-30
Filed2025-09-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 144
MetricValuePeriodScopeSource row
Revenue¥4.8bn2024-07-01 → 2025-06-30Cons.Net sales
Revenue¥5.2bn2023-07-01 → 2024-06-30Cons.Net sales
Revenue¥8.1bn2022-07-01 → 2023-06-30vCons.Net sales (5-year summary)
Revenue¥9.3bn2021-07-01 → 2022-06-30vCons.Net sales (5-year summary)
Revenue¥8.9bn2020-07-01 → 2021-06-30dCons.Net sales (5-year summary)
Operating income−¥138m2024-07-01 → 2025-06-30Cons.Operating income
Operating income−¥610m2023-07-01 → 2024-06-30Cons.Operating income
Ordinary income−¥129m2024-07-01 → 2025-06-30Cons.Ordinary income
Ordinary income−¥566m2023-07-01 → 2024-06-30Cons.Ordinary income
Ordinary income¥727m2022-07-01 → 2023-06-30vCons.Ordinary income loss (5-year summary)
Ordinary income¥1.3bn2021-07-01 → 2022-06-30vCons.Ordinary income loss (5-year summary)
Ordinary income¥920m2020-07-01 → 2021-06-30dCons.Ordinary income loss (5-year summary)
Profit before tax−¥220m2024-07-01 → 2025-06-30Cons.Income before income taxes
Profit before tax−¥615m2023-07-01 → 2024-06-30Cons.Income before income taxes
Net income (owners)−¥211m2024-07-01 → 2025-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥662m2023-07-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥452m2022-07-01 → 2023-06-30vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥810m2021-07-01 → 2022-06-30vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥562m2020-07-01 → 2021-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥211m2024-07-01 → 2025-06-30Cons.Profit loss
Net income−¥663m2023-07-01 → 2024-06-30Cons.Profit loss
Total assets¥6.8bnat 2025-06-30Cons.Assets
Total assets¥6.9bnat 2024-06-30Cons.Assets
Total assets¥8.2bnat 2023-06-30vCons.Total assets (5-year summary)
Total assets¥8.5bnat 2022-06-30vCons.Total assets (5-year summary)
Total assets¥7.1bnat 2021-06-30dCons.Total assets (5-year summary)
Total liabilities¥775mat 2025-06-30Cons.Liabilities
Total liabilities¥697mat 2024-06-30Cons.Liabilities
Net assets / equity¥6.0bnat 2025-06-30Cons.Net assets
Net assets / equity¥6.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥7.2bnat 2023-06-30vCons.Net assets
Net assets / equity¥6.8bnat 2022-06-30vCons.Net assets (5-year summary)
Net assets / equity¥6.2bnat 2021-06-30dCons.Net assets (5-year summary)
Cash and deposits¥5.0bnat 2025-06-30Cons.Cash and deposits
Cash and deposits¥4.8bnat 2024-06-30Cons.Cash and deposits
Cash & equivalents¥5.0bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥4.8bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.9bnat 2023-06-30vCons.Cash and cash equivalents
Cash & equivalents¥6.0bnat 2022-06-30vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.3bnat 2021-06-30dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥558m2024-07-01 → 2025-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥881m2023-07-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥102m2022-07-01 → 2023-06-30vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥107m2020-07-01 → 2021-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥389m2024-07-01 → 2025-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14m2023-07-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥160m2022-07-01 → 2023-06-30vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥245m2021-07-01 → 2022-06-30vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2020-07-01 → 2021-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥214,0002024-07-01 → 2025-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥261m2023-07-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2022-07-01 → 2023-06-30vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥130m2021-07-01 → 2022-06-30vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥131m2020-07-01 → 2021-06-30dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-8.052024-07-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-25.322023-07-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.272022-07-01 → 2023-06-30vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.952021-07-01 → 2022-06-30vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.492020-07-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥230.22at 2025-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥238.28at 2024-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥266.41at 2023-06-30vCons.Net assets per share (5-year summary)
Net assets per share¥254.14at 2022-06-30vCons.Net assets per share (5-year summary)
Net assets per share¥230.88at 2021-06-30dCons.Net assets per share (5-year summary)
Equity ratio88.4%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.7%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio84.6%at 2023-06-30vCons.Equity to asset ratio (5-year summary)
Equity ratio78.3%at 2022-06-30vCons.Equity to asset ratio (5-year summary)
Equity ratio84.5%at 2021-06-30dCons.Equity to asset ratio (5-year summary)
ROE6.6%2022-07-01 → 2023-06-30vCons.Rate of return on equity (5-year summary)
ROE12.8%2021-07-01 → 2022-06-30vCons.Rate of return on equity (5-year summary)
ROE9.7%2020-07-01 → 2021-06-30dCons.Rate of return on equity (5-year summary)
Employees81at 2025-06-30Cons.Number of employees
Employees90at 2024-06-30Cons.Number of employees
Employees98at 2023-06-30vCons.Number of employees
Employees100at 2022-06-30vCons.Number of employees
Employees104at 2021-06-30dCons.Number of employees
Revenue¥753m2024-07-01 → 2025-06-30StandaloneNet sales
Revenue¥304m2023-07-01 → 2024-06-30StandaloneNet sales
Revenue¥377m2022-07-01 → 2023-06-30vStandaloneNet sales (5-year summary)
Revenue¥439m2021-07-01 → 2022-06-30vStandaloneNet sales (5-year summary)
Revenue¥425m2020-07-01 → 2021-06-30dStandaloneNet sales (5-year summary)
Operating income¥409m2024-07-01 → 2025-06-30StandaloneOperating income
Operating income−¥6m2023-07-01 → 2024-06-30StandaloneOperating income
Ordinary income¥420m2024-07-01 → 2025-06-30StandaloneOrdinary income
Ordinary income¥2m2023-07-01 → 2024-06-30StandaloneOrdinary income
Ordinary income¥87m2022-07-01 → 2023-06-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥137m2021-07-01 → 2022-06-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥132m2020-07-01 → 2021-06-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥388m2024-07-01 → 2025-06-30StandaloneIncome before income taxes
Profit before tax−¥9m2023-07-01 → 2024-06-30StandaloneIncome before income taxes
Net income¥448m2024-07-01 → 2025-06-30StandaloneProfit loss
Net income−¥10m2023-07-01 → 2024-06-30StandaloneProfit loss
Net income¥142m2022-07-01 → 2023-06-30vStandaloneNet income loss (5-year summary)
Net income¥195m2021-07-01 → 2022-06-30vStandaloneNet income loss (5-year summary)
Net income¥288m2020-07-01 → 2021-06-30dStandaloneNet income loss (5-year summary)
Total assets¥4.7bnat 2025-06-30StandaloneAssets
Total assets¥4.2bnat 2024-06-30StandaloneAssets
Total assets¥4.3bnat 2023-06-30vStandaloneTotal assets (5-year summary)
Total assets¥4.5bnat 2022-06-30vStandaloneTotal assets (5-year summary)
Total assets¥4.2bnat 2021-06-30dStandaloneTotal assets (5-year summary)
Total liabilities¥59mat 2025-06-30StandaloneLiabilities
Total liabilities¥29mat 2024-06-30StandaloneLiabilities
Net assets / equity¥4.6bnat 2025-06-30StandaloneNet assets
Net assets / equity¥4.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2023-06-30vStandaloneNet assets
Net assets / equity¥4.3bnat 2022-06-30vStandaloneNet assets (5-year summary)
Net assets / equity¥4.2bnat 2021-06-30dStandaloneNet assets (5-year summary)
Cash and deposits¥2.4bnat 2025-06-30StandaloneCash and deposits
Cash and deposits¥1.2bnat 2024-06-30StandaloneCash and deposits
EPS (basic)¥17.112024-07-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-0.42023-07-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥5.442022-07-01 → 2023-06-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥7.472021-07-01 → 2022-06-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.022020-07-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥52024-07-01 → 2025-06-30StandaloneDividend paid per share (5-year summary)
Dividend per share¥52022-07-01 → 2023-06-30vStandaloneDividend paid per share (5-year summary)
Dividend per share¥52021-07-01 → 2022-06-30vStandaloneDividend paid per share (5-year summary)
Dividend per share¥52020-07-01 → 2021-06-30dStandaloneDividend paid per share (5-year summary)
Net assets per share¥175.67at 2025-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥158.55at 2024-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥163.95at 2023-06-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥163.52at 2022-06-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥161.05at 2021-06-30dStandaloneNet assets per share (5-year summary)
Equity ratio98.7%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio99.3%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2023-06-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio95.6%at 2022-06-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2021-06-30dStandaloneEquity to asset ratio (5-year summary)
ROE10.2%2024-07-01 → 2025-06-30StandaloneRate of return on equity (5-year summary)
ROE3.3%2022-07-01 → 2023-06-30vStandaloneRate of return on equity (5-year summary)
ROE4.6%2021-07-01 → 2022-06-30vStandaloneRate of return on equity (5-year summary)
ROE7.0%2020-07-01 → 2021-06-30dStandaloneRate of return on equity (5-year summary)
Shares issued26,158,200at 2025-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2023-06-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2022-06-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2021-06-30dStandaloneTotal number of issued shares (5-year summary)
Employees9at 2025-06-30StandaloneNumber of employees
Employees11at 2024-06-30StandaloneNumber of employees
Employees7at 2023-06-30vStandaloneNumber of employees
Employees9at 2022-06-30vStandaloneNumber of employees
Employees8at 2021-06-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 95
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-07-01 → 2025-06-30¥548,000
Reconciling Itemsreconcilingdepreciation2024-07-01 → 2025-06-30¥557,000
Reconciling Itemsreconcilingrevenue2024-07-01 → 2025-06-30−¥26m
Reconciling Itemsreconcilingrevenue external2024-07-01 → 2025-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2024-07-01 → 2025-06-30−¥28m
Reconciling Itemsreconcilingsegment assetsat 2025-06-30¥2.8bn
Reconciling Itemsreconcilingsegment profit2024-07-01 → 2025-06-30−¥343m
Clinical Evidence Servicereportable segmentcapex2024-07-01 → 2025-06-30¥4m
Clinical Evidence Servicereportable segmentdepreciation2024-07-01 → 2025-06-30¥6m
Clinical Evidence Servicereportable segmentemployeesat 2025-06-3013 pure
Clinical Evidence Servicereportable segmentrevenue2024-07-01 → 2025-06-30¥242m
Clinical Evidence Servicereportable segmentrevenue external2024-07-01 → 2025-06-30¥242m
Clinical Evidence Servicereportable segmentsegment assetsat 2025-06-30¥321m
Clinical Evidence Servicereportable segmentsegment profit2024-07-01 → 2025-06-30¥9m
Functional Cosmetic Retailingreportable segmentcapex2024-07-01 → 2025-06-30¥30m
Functional Cosmetic Retailingreportable segmentdepreciation2024-07-01 → 2025-06-30¥2m
Functional Cosmetic Retailingreportable segmentemployeesat 2025-06-3023 pure
Functional Cosmetic Retailingreportable segmentrevenue2024-07-01 → 2025-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentrevenue external2024-07-01 → 2025-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2025-06-30¥745m
Functional Cosmetic Retailingreportable segmentsegment profit2024-07-01 → 2025-06-30¥27m
Functional Food Retailingreportable segmentcapex2024-07-01 → 2025-06-30¥357,000
Functional Food Retailingreportable segmentdepreciation2024-07-01 → 2025-06-30¥8m
Functional Food Retailingreportable segmentemployeesat 2025-06-3019 pure
Functional Food Retailingreportable segmentrevenue2024-07-01 → 2025-06-30¥2.1bn
Functional Food Retailingreportable segmentrevenue external2024-07-01 → 2025-06-30¥2.1bn
Functional Food Retailingreportable segmentrevenue intersegment2024-07-01 → 2025-06-30¥13m
Functional Food Retailingreportable segmentsegment assetsat 2025-06-30¥1.1bn
Functional Food Retailingreportable segmentsegment profit2024-07-01 → 2025-06-30¥91m
Functional Material Developmentreportable segmentdepreciation2024-07-01 → 2025-06-30¥297,000
Functional Material Developmentreportable segmentemployeesat 2025-06-306 pure
Functional Material Developmentreportable segmentrevenue2024-07-01 → 2025-06-30¥298m
Functional Material Developmentreportable segmentrevenue external2024-07-01 → 2025-06-30¥283m
Functional Material Developmentreportable segmentrevenue intersegment2024-07-01 → 2025-06-30¥15m
Functional Material Developmentreportable segmentsegment assetsat 2025-06-30¥1.3bn
Functional Material Developmentreportable segmentsegment profit2024-07-01 → 2025-06-30−¥28m
Health Care Support Servicereportable segmentcapex2024-07-01 → 2025-06-30¥3m
Health Care Support Servicereportable segmentdepreciation2024-07-01 → 2025-06-30¥1m
Health Care Support Servicereportable segmentemployeesat 2025-06-3011 pure
Health Care Support Servicereportable segmentrevenue2024-07-01 → 2025-06-30¥688m
Health Care Support Servicereportable segmentrevenue external2024-07-01 → 2025-06-30¥688m
Health Care Support Servicereportable segmentsegment assetsat 2025-06-30¥528m
Health Care Support Servicereportable segmentsegment profit2024-07-01 → 2025-06-30¥107m
—segment totalcapex2024-07-01 → 2025-06-30¥37m
—segment totaldepreciation2024-07-01 → 2025-06-30¥18m
—segment totalrevenue2024-07-01 → 2025-06-30¥4.9bn
—segment totalrevenue external2024-07-01 → 2025-06-30¥4.8bn
—segment totalrevenue intersegment2024-07-01 → 2025-06-30¥28m
—segment totalsegment assetsat 2025-06-30¥4.0bn
—segment totalsegment profit2024-07-01 → 2025-06-30¥205m
Reconciling Itemsreconcilingcapex2023-07-01 → 2024-06-30¥798,000
Reconciling Itemsreconcilingdepreciation2023-07-01 → 2024-06-30¥231,000
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-06-30−¥43m
Reconciling Itemsreconcilingrevenue external2023-07-01 → 2024-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-06-30−¥44m
Reconciling Itemsreconcilingsegment assetsat 2024-06-30¥1.4bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-06-30−¥309m
Clinical Evidence Servicereportable segmentcapex2023-07-01 → 2024-06-30¥7m
Clinical Evidence Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥5m
Clinical Evidence Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥236m
Clinical Evidence Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥221m
Clinical Evidence Servicereportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥15m
Clinical Evidence Servicereportable segmentsegment assetsat 2024-06-30¥298m
Clinical Evidence Servicereportable segmentsegment profit2023-07-01 → 2024-06-30−¥70m
Functional Cosmetic Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥6m
Functional Cosmetic Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥11m
Functional Cosmetic Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2024-06-30¥2.6bn
Functional Cosmetic Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥153m
Functional Food Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥310,000
Functional Food Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥9m
Functional Food Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥10m
Functional Food Retailingreportable segmentsegment assetsat 2024-06-30¥1.0bn
Functional Food Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥158m
Functional Material Developmentreportable segmentdepreciation2023-07-01 → 2024-06-30¥928,000
Functional Material Developmentreportable segmentrevenue2023-07-01 → 2024-06-30¥318m
Functional Material Developmentreportable segmentrevenue external2023-07-01 → 2024-06-30¥299m
Functional Material Developmentreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥19m
Functional Material Developmentreportable segmentsegment assetsat 2024-06-30¥1.3bn
Functional Material Developmentreportable segmentsegment profit2023-07-01 → 2024-06-30−¥13m
Health Care Support Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥353,000
Health Care Support Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentsegment assetsat 2024-06-30¥382m
Health Care Support Servicereportable segmentsegment profit2023-07-01 → 2024-06-30¥93m
—segment totalcapex2023-07-01 → 2024-06-30¥13m
—segment totaldepreciation2023-07-01 → 2024-06-30¥27m
—segment totalrevenue2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue external2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue intersegment2023-07-01 → 2024-06-30¥44m
—segment totalsegment assetsat 2024-06-30¥5.6bn
—segment totalsegment profit2023-07-01 → 2024-06-30−¥301m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,294
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)あると築地有限責任監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)長井 完文
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)曽川 俊洋
Key audit matters consolidated (text)FilingDateInstantText · Plus
Overview kam consolidated (text)FilingDateInstantText · Plus
Short description kam consolidatedFilingDateInstant_Row1Member
Original text (Japanese)化粧品事業セグメントにおける中国市場向けの売上高に係る収益認識の適切性
Description including reason kam consolidated (text)FilingDateInstant_Row1MemberText · Plus
Auditors response kam consolidated (text)FilingDateInstant_Row1MemberText · Plus
Other information consolidated (text)FilingDateInstantText · Plus
Fee related information consolidated (text)FilingDateInstantText · Plus
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)あると築地有限責任監査法人
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)長井 完文
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)曽川 俊洋
Key audit matters non consolidated (text)FilingDateInstantText · Plus
Overview kam non consolidated (text)FilingDateInstantText · Plus
Other information non consolidated (text)FilingDateInstantText · Plus
Fee related information non consolidated (text)FilingDateInstantText · Plus
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior4YearDuration8942496000JPY
Net sales (5-year summary)Prior3YearDuration9347879000JPY
Net sales (5-year summary)Prior2YearDuration8079926000JPY
Net sales (5-year summary)Prior1YearDuration5158458000JPY
Net sales (5-year summary)CurrentYearDuration4848534000JPY
Ordinary income loss (5-year summary)Prior4YearDuration920040000JPY
Ordinary income loss (5-year summary)Prior3YearDuration1253893000JPY
Ordinary income loss (5-year summary)Prior2YearDuration727175000JPY
Ordinary income loss (5-year summary)Prior1YearDuration-565818000JPY
Ordinary income loss (5-year summary)CurrentYearDuration-129012000JPY
Profit loss attributable to owners of parent (5-year summary)Prior4YearDuration562061000JPY
Profit loss attributable to owners of parent (5-year summary)Prior3YearDuration809710000JPY
Profit loss attributable to owners of parent (5-year summary)Prior2YearDuration451847000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration-662203000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYearDuration-210696000JPY
Comprehensive income (5-year summary)Prior4YearDuration580774000JPY
Comprehensive income (5-year summary)Prior3YearDuration817198000JPY
Comprehensive income (5-year summary)Prior2YearDuration455641000JPY
Comprehensive income (5-year summary)Prior1YearDuration-663054000JPY
Comprehensive income (5-year summary)CurrentYearDuration-211368000JPY
Net assets (5-year summary)Prior4YearInstant6231537000JPY
Net assets (5-year summary)Prior3YearInstant6847367000JPY
Net assets (5-year summary)Prior2YearInstant7172217000JPY
Net assets (5-year summary)Prior1YearInstant6249110000JPY
Net assets (5-year summary)CurrentYearInstant6037741000JPY
Total assets (5-year summary)Prior4YearInstant7146534000JPY
Total assets (5-year summary)Prior3YearInstant8489524000JPY
Total assets (5-year summary)Prior2YearInstant8239982000JPY
Total assets (5-year summary)Prior1YearInstant6946134000JPY
Total assets (5-year summary)CurrentYearInstant6812899000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-06-30pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
balance sheet identitynon_consolidated 2024-06-30pass
balance sheet identitynon_consolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net assetsnon_consolidated 2023-06-30pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · net assetsnon_consolidated 2025-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-07-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2024-07-01/2025-06-30pass
statement vs summary · revenueconsolidated 2023-07-01/2024-06-30pass
statement vs summary · revenueconsolidated 2024-07-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2023-07-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2024-07-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-06-30pass
statement vs summary · total assetsconsolidated 2025-06-30pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass
statement vs summary · total assetsnon_consolidated 2025-06-30pass